ACP
IBIO icon

Aveo Capital Partners’s iBio IBIO Stock Holding History

Aveo Capital Partners’s Portfolio IBIO Stock Details IBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-14
Closed -$13K – 148
2017
Q4 		$13K Hold
14
– – ﹤0.01% 144
2017
Q3 		$23K Hold
14
– – 0.01% 135
2017
Q2 		$28K Hold
14
– – 0.01% 132
2017
Q1 		$31K Sell
14
-3
-18% -$6.24K 0.01% 129
2016
Q4 		$33K Buy
+17
New +$39.5K 0.01% 232

Other funds holding IBIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
S
SignatureFD Atlanta, Georgia $7.49B AUM 24.82% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Aveo Capital Partners's IBIO Position: Q1 2018 in Review

Aveo Capital Partners sold out of iBio (IBIO) in Q1 2018, closing a stake of 14 shares — an estimated $13K sold.

Aveo Capital Partners first reported a position in IBIO in Q4 2016 and held it in 5 quarters. The position peaked at $33K in Q4 2016. 20 funds tracked by Wall St. Rank hold IBIO as of Q1 2018.

  • Aveo Capital Partners reported no remaining iBio position as of Q1 2018 after selling out during the quarter.
  • Aveo Capital Partners sold 14 iBio shares in Q1 2018, an estimated $13K.
  • Aveo Capital Partners first reported a position in iBio in Q4 2016 and held it in 5 quarters.
  • Aveo Capital Partners's iBio position peaked at $33K in Q4 2016.
  • 20 funds tracked by Wall St. Rank held iBio as of Q1 2018.

Based on Aveo Capital Partners's 13F filing for Q1 2018, filed 11 May 2018.